Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Peripheral T-cell Lymphoma
Peripheral T-Cell Lymphoma
Enrolment: 67 · Results not recorded
Loading the evidence…
Drug · Mechanism not fully elucidated; potentially disruption of mitochondrial function, production of reactive oxygen species, modulation of signal transduction pathways (ChEMBL mechanism_comment). ATC L01XX82.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Peripheral T-Cell Lymphoma
Enrolment: 67 · Results not recorded
Hematologic Neoplasms · Bone Marrow Neoplasms · Non-Hodgkin's Lymphoma
Enrolment: 50 · Results not recorded
Multiple Myeloma
Enrolment: 35 · Results not recorded
Peripheral T-cell Lymphoma
Enrolment: 17 · Results not recorded
Solid Tumors
Enrolment: 40 · Results not recorded
Acute Leukemia · Multiple Myeloma · Lymphoma · Myelodysplasia
Enrolment: 12 · Results not recorded
Advanced Solid Tumors
Enrolment: 12 · Results not recorded
Advanced Solid Tumors · Lymphomas
Enrolment: 20 · Results not recorded
Advanced Cancer
Enrolment: 23 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Ionising radiation-induced acute gastrointestinal syndrome; parallel orthotopic xenograft model of prostate cancer
Darinaparsin given before irradiation accelerated recovery from body weight loss and increased survival in the radiation-induced gastrointestinal syndrome model, and decreased post-irradiation DNA damage and cell death in crypt epithelial cells. Cell cycle arrest at G1/S and G2/M with induction of…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.